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Genetic variation in the 6p21 chromosomal region, including human leukocyte antigen (HLA)
genes and tumor necrosis factor (TNF), has been linked to both etiology and clinical outcomes
of lymphomas. We estimated the effects of HLA class I (A, B, and C), class II DRB1 alleles,
and the ancestral haplotype (AH) 8.1 (HLA A∗01-B∗08-DRB1∗03-TNF-308A) on overall survival
(OS) among patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)
in a population-based study of non-Hodgkin lymphoma. During a median followup of 89 months,
31% (52 of 166) DLBCL and 28% (46 of 165) FL patients died. Using multivariate Cox regression
models, we observed statistically signiﬁcant associations between genetic variants and survival:
HLA-Cw∗07:01 was associated with poorer OS among DLBCL patients (Hazard ratio [HR]=1.76,
95% conﬁdence interval [CI]=1.01–3.05); HLA-A∗01:01 was associated with poorer OS (HR
=2.23, 95% CI=1.24–4.01), and HLA-DRB1∗13 (HR=0.12, 95% CI=0.02–0.90) and HLA-B Bw4
(HR=0.36, 95% CI=0.20–0.63) with better OS among FL patients. These results support a role
for HLA in the prognosis of DLBCL and FL and represent a promising class of prognostic factors
that warrants further evaluation.
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1. INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the two most commonly
diagnosed subtypes of non-Hodgkin lymphoma (NHL) in the United States. The established prognostic
factors for DLBCL as delineated in the International Prognostic Factor Index (IPI) include age, clinical
stage, number of extranodal sites, performance score, and lactate dehydrogenase level [1]; the established
prognostic factors for FL as validated by the Follicular Lymphoma International Prognostic Index (FLIPI)
include age, clinical stage, number of nodal areas, hemoglobin level, and lactate dehydrogenase level [2].
However, the clinical course of both diseases is variable, and both IPI and FLIPI predict prognosis incom-
pletely. Patient genetic variation may improve predicted prognosis after diagnosis with DLBCL and FL.
Genetic variation in the 6p21 chromosomal region has been linked to both etiology and clinical
courses of lymphomas and related risk factors. The 6p21 chromosomal region houses the major histocom-
patibility complex, which includes the human leukocyte antigen (HLA) genes and tumor necrosis factor
(TNF). TNF and the ancestral HLA haplotype 8.1, which includes TNF, (AH 8.1: HLA A∗01-B∗08-
DRB1∗03-TNF-308A) have been implicated in DLBCL etiology in epidemiology studies [3] and NHL
survival in a series of clinical studies [4–7]. In our etiological investigations, we have also reported asso-
ciations between HLA-DRB1∗04:01 with DLBCL risk and HLA-DRB1∗13 and HLA-DRB1∗01:01 with FL
risk [8], the latter of which has been corroborated in a genome-wide association study (GWAS) [9]. In
addition, all HLA-B alleles can be further grouped (mutually exclusively) as HLA-B Bw4 or Bw6 based on
amino acid residues at positions 79–83, and HLA-B Bw4 has been associated with and has delayed pro-
gression to acquired immunodeﬁciency syndrome (AIDS) among those with the human immunodeﬁcien-
cy virus (HIV), a known risk factor for NHL [10].
Here, we evaluate whether these previously implicated alleles, other HLA class I (A, B, C) and class
II DRB1 alleles, and AH 8.1 are associated with DLBCL and FL survival in a multicenter population-based
study of NHL in the United States.
2. METHODS
Details of the National Cancer Institute-Surveillance, Epidemiology and End Results (NCI-SEER) NHL
population-based case-control study have been described elsewhere [4, 8, 11]. Brieﬂy, 1,321 newly diag-
nosed and histologically conﬁrmed NHL patients, aged 20–74 years, were identiﬁed in four SEER registries
(Iowa; Detroit, Mich; Los Angeles, Calif; Seattle, Wash) during July 1998–June 2000. Patients had no evi-
dence of HIV infection but testing for HIV was not conducted as part of the study. All participants provided
written informed consent and completed an in-person interview; 1172 (89%) provided either a venous blood
sample (n =773) or mouthwash buccal cell sample (n =399). Of 365 DLBCL (215 with blood) and 278FL
(192 with blood) cases enrolled in the study, the present analysis comprises the 179 DLBCL and 180FL
cases who had complete clinical and demographic information and sufﬁcient DNA for HLA allelotyping.
Characteristics for those with sufﬁcient DNA and those without sufﬁcient DNA were similar (data not
shown), making any potential biases for our results based on patients with sufﬁcient DNA unlikely.
Demographic information, including age, sex, race, Hispanic ethnicity, and education level, was de-
rived from patients’ interviews as part of the case-control study. Clinical information, including date of diag-
nosis, histology, stage, presence of B-symptoms, ﬁrst course of therapy, date of last followup, and vital
status, was derived from linkages to the SEER registry databases at each study site in 2008. Data on ﬁrst
course of therapy included use of single or multiagent chemotherapy, radiation, other therapies exclusive of
chemotherapy and/or radiation, and no therapy (observation); information on individual agents and doses
was not available. The SEER registries collect date and cause of death but do not collect data on treatment
response or disease recurrence or progression.
Pathology information was derived from abstracted reports by the local diagnosing pathologist. All
cases were coded according to the International Classiﬁcation of Diseases-Oncology (ICD-O), 2nd Edition,
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and updated to the WHO/ICD-O-3. DLBCL was deﬁned as ICD-O 9678, 9679, 9680, and 9684 and FL as
9690-9691, 9695, and 9698.
DNA was extracted using Puregene Autopure DNA extraction kits (Gentra Systems, Minneapolis,
Minn). Four-digit HLA Class I (A, B, and C) and Class II genotyping (DRB1) was conducted at NCI-
Frederick (Frederick, MD) according to sequence-speciﬁc oligonucleotide probe (SSOP) hybridization
and sequence-based typing protocols developed by the 13th International Histocompatibility Workshop.
Agreement for quality control duplicates (n = 100) was ≥99%. HLA alleles were deﬁned as presence (if
the individual had either one or two copies of the allele) or absence of the speciﬁc allele (deﬁn e da sh a v i n g
no copies of the allele). TNF genotyping was conducted at the National Cancer Institute Core Genotying
facility (Gaithersburg, MD, USA) using the Taqman (Foster City, Calif, USA) PLATFORM. TNF G-308A
was deﬁnedby genotype (GG (referent), GA, and AA). Haplotypes for HLA-A-B-DR were determined using
“FastHap”, which determines haplotypes by expectation maximization (http://home.ncifcrf.gov/ccr/lgd/
bioinformatics/index n.asp).
We ﬁt Cox proportional hazard regression models to estimate hazard ratios (HRs) and 95%
conﬁdence intervals (95% CIs) for the association of each individual HLA loci (e.g., HLA-A, -B, -C, or
-DRB1) and haplotype with overall survival, adjusting for demographic and clinical factors. Demographic
and clinical factors were modeled as one risk score, which was a linear combination of age (<60 versus
≥60 years), sex, race (white and all other), study center (Detroit, Iowa, Los Angeles, and Seattle), and years
of education (<12, 12–15, and ≥16 years), tumor stage (local, regional, distant, and missing), presence of B
symptoms (no, yes, missing), and type of initial therapy (chemotherapy plus radiation, chemotherapy plus
other therapy, radiation only, all other, or missing therapy) [4, 11]. Analyses were also conducted restricted
to non-Hispanic Caucasians. Two-sided P values were reported. All analyses were conducted using SAS
9.1.3 (SAS Institute, Cary, NC, USA).
3. RESULTS
Descriptive characteristics (demographic and clinical features) of our population are shown in Table 1.T h e
median age at diagnosis was 58 years for DLBCL patients (range, 20–74) and 56 years for FL patients
(range, 28–74) [8]. Male patients comprised 55% and 49% of DLBCL and FL, respectively. Ninety-two
percent DLBCL and FL patients identiﬁed themselves as non-Hispanic Caucasians. Thirty-eight percent of
DLBCL and 56% of FL patients had advanced stage (distant) disease. Twenty-four percent of DLBCL and
14% of FL patients had B symptoms. Chemotherapy-based regimen was the most common initial therapy.
With a median followup of 89 months (range, 7–112 months), 58 of 179 (32%) DLBCL and 48 of 180
(27%) FL patients died.
HLA Class I and II Alleles
Among FL cases, presence of HLA-A∗01:01 was associated with poorer OS (HR = 2.23, 95% CI = 1.24–
4.01), whereas the presence of HLA-B Bw4 (HR = 0.36, 95% CI = 0.20–0.63) and HLA-DRB1∗13 (HR =
0.12, 95% CI = 0.02–0.90) was associated with better OS (Table 2). The presence of HLA-Cw∗07:01 was
associated with poorer OS among DLBCL patients (HR = 1.76, 95% CI = 1.01–3.05).
AH 8.1
The AH 8.1 (HLA-A∗01-B∗08-DR∗03-TNF-308A) was associated with poorer OS among patients with FL,
likely due to a strong association with the HLA-A∗01-B∗08-DR∗03 haplotype (HR = 2.19, 95% CI = 1.08–
4.45), whereas TNF G-308A was not associated with survival after FL (Table 2). In contrast, among patients
with DLBCL, the AH 8.1 and HLA-A were not associated with OS, but the presence of the TNF-308A allele
was associated with poorer OS (HR for GA/AA versus GG = 1.79, 95% CI = 1.02–3.14).
Corresponding survival curves for each HLA allele and AH 8.1 association for DLBCL and FL are
shown in the Figure 1.
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TABLE 1: Demographic and clinical characteristics of DLBCL and FL patients from the NCI-SEER NHL
study for which HLA typing was conducted.
Characteristics
DLBCL FL
n (%) n (%)
Sex
Male 99 (55.3) 89 (49.4)
Female 80 (44.7) 91 (50.6)
Age (years)
<60 93 (52.0) 103 (57.2)
60+ 86 (48.0) 77 (42.8)
Race
Non-Hispanic Caucasian 165 (92.2) 165 (91.7)
Other 14 (7.8) 15 (8.3)
Study Center
Detroit 19 (10.6) 16 (8.9)
Iowa 67 (37.4) 76 (42.2)
Los Angeles 29 (16.2) 30 (16.7)
Seattle 64 (35.8) 58 (32.2)
Education (years)
<12 16 (8.9) 11 (6.1)
12–15 118 (65.9) 118 (65.6)
16+ 45 (25.1) 51 (28.3)
Stage
Local 69 (38.6) 44 (24.4)
Regional 39 (21.8) 25 (13.9)
Distant 38 (38.0) 101 (56.1)
Unknown 3 (1.7) 10 (5.6)
Presence of B symptoms
No 136 (76.0) 154 (85.6)
Yes 43 (24.0) 26 (14.4)
4. DISCUSSION
Our data suggest that speciﬁc HLA alleles are associated with survival among DLBCL and FL patients.
Speciﬁcally, HLA-Cw∗07:01 was associated with poorer OS among DLBCL patients, and HLA-A∗01:01
was associated with poorer OS and HLA-DRB1∗13 and HLA-B Bw4 with better OS among FL patients.
Overall, the results add to the growing body of evidence of a role for HLA in the prognosis of these subtypes.
Our results agree with various clinical studies [5–7, 12]i nw h i c hTNF G-308A and AH 8.1 have
been reported to inﬂuence clinical course and outcome of NHL overall. In one analysis restricted to DLBCL
patients, TNF-α in plasma predicted DLBCL survival [12], a pattern consistent with our study results that
TNF G-308A increases the risk of death among DLBCL patients. In that study, the authors also reported
that AH 8.1 predicted overall survival of NHL patients, and that HLA-A∗01 and HLA-B∗08 were associated
with prognosis [7]. In this study, AH 8.1 was associated with poorer OS among FL patients, a result that our
data suggest to be largely driven by the association with HLA-A∗01:01. Taken together, our results support
the hypothesis that chronic inﬂammation contributes to poorer prognosis of DLBCL, but other mechanisms
of immune dysregulation may further be considered for FL prognosis.
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TABLE 2: HLA class I and II alleles and haplotypes and their associations with overall survival among
diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) patients.
DLBCL FL
Allele/Haplotype Status
Total
no.
No. of
deaths
HR (95%CI)
Total
no.
No. of
deaths
HR (95%CI)
HLA class I
HLA-A∗01:01
Absent 107 31 1.00 (ref) 109 23 1.00 (ref)
Present 59 21 1.30 (0.74–2.26) 54 22 2.23 (1.24–4.01)
HLA-B∗08:01
Absent 123 35 1.00 (ref) 123 32 1.0 (ref)
Present 42 17 1.40 (0.78–2.51) 42 14 1.39 (0.74–2.61)
HLA-Cw∗07:01
Absent 111 28 1.00 (ref) 116 32 1.00 (ref)
Present 55 24 1.76 (1.01–3.05) 49 14 1.12 (0.60–2.10)
HLA-B Bw4
Absent 73 27 1.00 (ref) 55 25 1.00 (ref)
Present 106 31 0.97 (0.58–1.64) 125 23 0.36 (0.20–0.63)
HLA class II
HLA-DRB1∗01:01
Absent 134 43 1.00 (ref) 118 32 1.00 (ref)
Present 32 9 0.94 (0.46–1.94) 47 14 1.12 (0.59–2.10)
HLA-DRB1∗03:01
Absent 121 34 1.00 (ref) 127 33 1.00 (ref)
Present 45 18 1.41 (0.79–2.50) 38 13 1.33 (0.70–2.54)
HLA-DRB1∗13
Absent 137 39 1.00 (ref) 146 47 1.00 (ref)
Present 29 13 1.34 (0.71–2.55) 19 1 0.12 (0.02–0.90)
AH 8.1
HLA-A∗01-B∗08-DR∗03
Absent 135 40 1.00 (ref) 143 35 1.00 (ref)
Present 30 12 1.46 (0.76–2.80) 20 10 2.19 (1.08–4.45)
TNF G-308A
GG 98 26 1.00 (ref) 107 28 1.00 (ref)
GA 53 21 1.66 (0.93–2.97) 42 15 1.52 (0.81–2.86)
AA 6 3 3.81 (1.13–12.9) 4 1 0.84 (0.11–6.19)
GA/AA 59 24 1.79 (1.02–3.14) 46 16 1.45 (0.78–2.68)
HLA-A∗01-B∗08- Absent 132 39 1.00 (ref) 135 34 1.00 (ref)
DR∗03-TNF-A Present 29 11 1.39 (0.71–2.73) 20 10 2.13 (1.05–4.34)
All models adjusted for the risk score that combined both demographic and clinical information.
The total numbers for each allele may differ due to laboratory interpretation of each allele which was done individually (e.g., ambiguous results for
each allele were excluded from analysis rather than presumed to be absent).
We previously reported that the HLA-DRB1∗13 group of alleles were associated with decreased risk
of developing FL. The newly identiﬁed association with better survival, if conﬁrmed in other data, would
implicate an important HLA allele in both FL etiology and survival. We also found better OS among FL
patients with HLA-B Bw4, suggesting possible similarities in mechanisms by which HLA-B Bw4 slows the
progression to AIDs. On the other hand, we did not observe a joint relationship between HLA-B Bw4 with
the KIR receptor (KIR3DS1), as has been reported for AIDS outcomes (data not shown) [10]. These results
support the potential role for the innate immune response and immune surveillance as important aspects for
FL etiology and prognosis.
We also report here that HLA-Cw∗07:01 was associated with poorer OS among DLBCL patients,
which was not found in a previous study [7]. This inconsistency could reﬂect chance, heterogeneity of
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FIGURE 1: Continued.
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FIGURE 1: Survival curves and Kaplan-Meier P-values among patients with DLBCL and FL by HLA alleles
and haplotype: (a) AH 8.1;( b )HLA-DRB1∗13;( c )HLA-Bw4;( d )HLA-A∗01:01;( e )HLA-Cw07:01.
the NHL deﬁnition in the previous clinical studies where the authors examined the risk of NHL overall
instead of by subtype [5–7], or dilution of the moderate association in the broad NHL deﬁnition compared
to analysis speciﬁc to DLBCL.
We note that most of of the HLA alleles identiﬁed as potentially relevant for etiology were not
predictive for survival, suggesting distinct functions for these genetic variations [8]. Alleles previously
found associated with NHL etiology in our study included HLA-A∗26:01, A∗29:02, B∗51:01, Cw∗03:04,
Cw∗15:02, DRB1∗04:01, and HLA-DRB1∗01:01 [8], none of which were identiﬁed as associated with
survival after DLBCL or FL.
An important strength of our study was the population-based ascertainment of newly diagnosed
cases, making our results more applicable to community-based treatment programs. Furthermore, we were
able to evaluate the results by subtype, whereas most clinical studies have only assessed the association for
NHL overall [5–7]. One important potential limitation apart from sample size is the lack of detailed data
on prognostic factors or treatment and that we missed most DLBCL deaths that occurred in the ﬁrst year.
By using age, stage, B symptoms, and treatment class, we, nonetheless, could predict survival with a level
of ability similar to the IPI for a large study of DLBCL and FL patients [4, 11]. Because all patients were
initially treated before the widespread use of rituximab, it will be important to evaluate a patient population
treated with rituximab alone (for both DLBCL and FL) and in combination with CHOP chemotherapy (for
DLBCL).
In summary, our results support a role for HLA in overall survival of DLBCL and FL patients, after
accounting for demographic and clinical factors. Our results are consistent with the emerging signiﬁcance
of the complex host genetic background in progression of each NHL subtype. Host immunogenetics,
particularly the major histocompatibility region that houses a number of immune genes including HLA,
represent a promising class of prognostic factors that warrant further evaluation.
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